UCSD Moores Cancer Center expert available to discuss breast brachytherapy

NewsGuard 100/100 Score

Recent controversy about breast brachytherapy - a shorter course of radiation treatment for breast cancer - has called into question whether the technique is being offered to too many women. New research on an advanced form of brachytherapy is now being reported by UC San Diego Moores Cancer Center and 11 other centers in the United States. These studies report highly favorable outcomes for a form of breast brachytherapy called SAVI.

Study leader and brachytherapy pioneer, Catheryn Yashar, MD, UC San Diego Moores Cancer Center, is available to discuss the data and the issues.

The new data, being presented this spring at several major conferences, show low rates of side effects and complications that are equivalent to traditional whole-breast irradiation (WBI). In contrast to WBI, the FDA-cleared breast brachytherapy takes only five days instead of six weeks, causing far less fatigue and allowing women to return to normal daily life much more quickly.

The new studies challenge skeptics' concerns that too many women may be receiving breast brachytherapy and will no doubt spark a new round of discussion about the best way to treat early-stage breast cancer.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels